CLBIO — Corline Biomedical AB Share News
0.000.00%
- SEK371.09m
- SEK338.10m
- SEK7.65m
Brief: Corline Biomedical Q2 Pre-Tax Loss At SEK 2.6 Mln
Brief: Corline Biomedical: Results Of First Study Of Drug Candidate Renaparin
Brief: Corline Biomedical Q1 Pre-tax Loss Narrows To SEK 2.5 Mln
Brief: Corline Biomedical Completes Patient Recruitment
Brief: Corline Biomedical Q4 Operating Loss Widens To SEK 2.1 Mln
Brief: Corline Biomedical Chooses Abzena As Partner For Clinical Trial Phase 2
Brief: Corline Biomedical Gets Positive Feedback From FDA Regarding Co's Planned Phase 2 Study
Brief: Corline Biomedical Q3 Pre-Tax Loss Widens To SEK 1.9 Mln
Brief: Corline Biomedical Starts Cooperation With UHN Toronto
Brief: Corline Biomedical Q2 Pre-Tax Loss Widens To SEK 2.5 Mln
Brief: Corline Biomedical Decides To Carry Out Directed New Issue
Brief: Corline Biomedical Q1 Pre-Tax Loss Widens To SEK 3.0 Mln
Brief: Corline Biomedical Q4 Pre-Tax Loss Flat At SEK 1.7 Million
Brief: Corline Biomedical Q3 Pre-Tax Loss Widens To SEK 1.5 Mln
Brief: Corline Biomedical Q2 Pre-Tax Loss Sek 1.9 Million
Brief: Corline Biomedical AB Gets Patent Approval In China
Brief: Corline Biomedical Q1 Pre-Tax Loss Narrows To SEK 1.8 Million
Brief: Corline Biomedical Enters Term Sheet Regarding Medical Technology Application
Brief: Corline Biomedical Q4 Pre-Tax Loss At SEK 1.7 Million